Pharmacotherapy for children and adolescents with epilepsy

Bibliography

• Connock M, Frew E, Evans BW, The clinical effectiveness and cost-effectiveness of newer drugs for children with epilepsy. A systematic review. Health Technol Assess 2006;10(7):118
   Google Scholar
• Pellock JM, Watemberg N. New antiepileptic drugs in children: present and future. Semin Pediatr Neurol 1997;4:9-18
   PubMedGoogle Scholar
• Hadjiloizou SM, Bourgeois BF. Antiepileptic drug treatment in children. Expert Rev Neurother 2007;7:179-93
   PubMedGoogle Scholar
• Lerman P, Kivity-Ephraim S. Carbamazepine efficacy and utilization in children. Epilepsia 1974;15:229-34
   PubMed Web of Science ®Google Scholar
• Levy RH, Mattson RH, Meldrum BS, Perucca E. Antiepileptic drugs. 5th edition. Lippincott Williams & Wilkins; 1992
   Google Scholar
• Zimmermann FT, Burgmeister BB. A new drug for petit mal epilepsy. Neurology 1958;8:769-75
   PubMedGoogle Scholar
• Capovilla G, Beccaria F, Veggiotti P, Ethosuximide is effective in the treatment of epileptic negative myoclonus in childhood partial epilepsy. J Child Neurol 1999;14:395-400
   PubMedGoogle Scholar
• Hvidberg EF, Dam M. Clinical pharmacokinetics of anticonvulsants. Clin Pharmacokinet 1976;1:161
   PubMedGoogle Scholar
• Mattson RH, Cramer JA. Valproic acid and ethosuximide interaction. Ann Neurol 1980;7:583-4
   PubMed Web of Science ®Google Scholar
• Mattson R, Ccramer J, Collins J, Comparison of carbamazepine, phenobarbital, phenytoin and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985;313:145-51
   PubMed Web of Science ®Google Scholar
• Farwell JR, Lee YJ, Hirtz DG, Phenobarbital for febrile seizures – effects on intelligence and on seizure recurrence. N Engl J Med 1990;322:364-9
   PubMed Web of Science ®Google Scholar
• Riva D, Devoti M. Discontinuation of phenobarbital in children: effects on neurocognitive behavior. Pediatr Neurol 1996;14:36-40
   PubMedGoogle Scholar
• Vining EPG, Mellitis ED, Dorsen MM, Psychologic and behavioral effects of antiepileptic drugs in children: a double-blind comparison between phenobarbital and valproic acid. Pediatrics 1987;80:165-74
   PubMed Web of Science ®Google Scholar
• Banu SH, Jahan M, Koli UK, Side effects of phenobarbital and carbamazepine in childhood epilepsy: randomised controlled trial. BMJ 2007;334:1207
   PubMedGoogle Scholar
• Pal DK, Das T, Chaudhury G, Randomised controlled trial to assess acceptability of phenobarbital for childhood epilepsy in rural India. Lancet 1998;351:19-23
   PubMedGoogle Scholar
• Hahn TJ. Serum 25-hydroxycalciferol levels and bone mass in children on chronic anticonvulsant therapy. N Engl J Med 1975;292:550
   Web of Science ®Google Scholar
• Mitchell W, Chavez J. Carbamazepine versus Phenobarbital for partial onset seizures in children. Epilepsia 1987;28:56-60
   PubMedGoogle Scholar
• Perucca E. In: Levy RH, Mattson RH, Meldrum BS, editors, Antiepileptic drugs. 5th edition. Lippincott Williams & Wilkins; 2002
   Google Scholar
• Merritt HH, Putnam TJ. Sodium diphenyl hydantoinate in the treatment of convulsive disorders. JAMA 1938;11:1068-73
   Google Scholar
• Yaari Y, Selzer ME, Pincus JH. Phenytoin: mechanisms of its anticonvulsant action. Ann Neurol 1986;20:171-84
   PubMed Web of Science ®Google Scholar
• Anast CS. Anticonvulsant drugs and calcium metabolism. N Engl J Med 1975;292:587-8
   Google Scholar
• Leppik IE, Boucher BA, Wilder BJ, Pharmacokinetics and safety of a phenytoin prodrug given IV or IM in patients. Neurology 1990;40:456-60
   PubMed Web of Science ®Google Scholar
• Verrotti A, Coppola G, Parisi P, Bone and calcium metabolism and antiepileptic drugs. Clin Neurol Neurosurg 2010;112:1-10
   PubMed Web of Science ®Google Scholar
• Bryant A, Dreifuss FE. Valproic acid hepatic fatalities. III. U.S. experience since 1986. Neurology 1996;46:465-9
   PubMed Web of Science ®Google Scholar
• Asconape JJ, Penry JK, Dreifuss FE, Valproate-associated pancreatitis. Epilepsia 1993;4:177-83
   Google Scholar
• Verrotti A, D'Egidio C, Coppola G, Epilepsy, sex hormones and antiepileptic drugs in female patients. Expert Rev Neurother 2009;9(12):1803-14
   PubMedGoogle Scholar
• Jeavons PM, Clark JE, Maheshwari MC. Treatment of generalized epilepsies of childhood and adolescence with sodium valproate. Dev Med Child Neurol 1977;19:9-25
   PubMed Web of Science ®Google Scholar
• Ramsay RE, Wilder BJ, Murphy JV, Efficacy and safety of valproic acid versus phenytoin as sole therapy for newly diagnosed primary generalized tonic-clonic seizures. J Epilepsy 1992;5:55-60
   Google Scholar
• Spitz MC, Deasy DN. Conversion to valproate monotherapy in nonretarded adults with primary generalized tonic-clonic seizures. J Epilepsy 1991;4:33-8
   Google Scholar
• Dulac O, Steru D, Rey E, Sodium valproate monotherapy in childhood epilepsy. Brain Dev 1986;8:47-52
   PubMed Web of Science ®Google Scholar
• Covanis A, Gupta AK, Jeavons PM. Sodium valproate: monotherapy and polytherapy. Epilepsia 1982;23:693-720
   PubMed Web of Science ®Google Scholar
• Bourgeois B, Beaumanoir A, Blajev B, Monotherapy with valproate in primary generalized epilepsies. Epilepsia 1987;28(Suppl 2):S8-11
   PubMedGoogle Scholar
• Barnes SE, Bower BD. Sodium valproate in the treatment of intractable childhood epilepsy. Dev Med Child Neurol 1975;17:175-81
   PubMedGoogle Scholar
• Yokoyama S, Kodama S, Ogini H. Study of the treatment of infantile spasms. Brain Dev 1976;8:447-53
   Google Scholar
• Brachet-Liermain A, Demarquez JL. Pharmacokinetics of dipropylacetate in infants and young children. Pharm Week 1977;112:293-7
   Google Scholar
• Marson AG, Al-Kharusi AM, Alwaidh M, The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial'. Lancet 2007;369:1016-26
   PubMed Web of Science ®Google Scholar
• Graves NM, Leppik IE. Advances in pharmacotherapy: recent developments in the treatment of epilepsy. J Clin Pharm Ther 1993;18:227-42
   PubMed Web of Science ®Google Scholar
• Hancock E, Cross H. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev 2003;3:CD003277
   Google Scholar
• Brodie MJ. Felbamate: a new antiepileptic drug. Lancet 1993;341:1445-6
   PubMedGoogle Scholar
• White HS. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia 1999;4(5):S2-10
   Google Scholar
• Sanka R, Holmes GL. Mechanisms of action for the commonly-used antiepileptic drugs: relevance to antiepileptic drug-associated neurobehavioral adverse effects. J Child Neurol 2004;19(Suppl 1):S6-14
   PubMedGoogle Scholar
• Sachdeo R, Narang-Sachdeo SK, Shumaker RC, Tolerability and pharmacokinetics of monotherapy felbamate doses of 1200–6000 mg/day in subjects with epilepsy. Epilepsia 1997;38:887-92
   PubMedGoogle Scholar
• Kelley MT, Walson PD, Cox S, Dusci LJ. Population pharmacokinetics of felbamate in children. Ther Drug Monit 1997;19(1):29-36
   PubMedGoogle Scholar
• Anonymous. Recommendation for the immediate withdrawal of patients from treatment with Felbatol(R) (felbamate). FDA Med Bull 1994;24(2):5
   Google Scholar
• Pellock JM, Brodie MJ. Felbamate: update. Epilepsia 1997;38(12):1261-4
   PubMedGoogle Scholar
• Jarrar RG, Buchhalter JR. Therapeutics in pediatric epilepsy, Part 1: the new antiepileptic drugs and the ketogenic diet. Mayo Clin Proc 2003;78:359-70
   PubMedGoogle Scholar
• The Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med 1993;328(1):29-33
   PubMedGoogle Scholar
• Siegel H, Kelley K, Stertz B, The efficacy of felbamate as add-on therapy to valproic acid in the Lennox-Gastaut syndrome. Epilepsy Res 1999;34(2-3):91-7
   PubMedGoogle Scholar
• Faught E, Sachdeo RC, Remler MP, Felbamate monotherapy for partial-onset seizures:an active-control trial. Neurology 1994;43:688-92
   Google Scholar
• Zupanc ML, Werner R, Arentz L. Efficacy of felbamate in the treatment of medically refractory epilepsy in children [abstract]. Epilepsia 2003;44:273
   PubMedGoogle Scholar
• Cilio MR, Kartashov AI, Vigevano F. The long-term use of felbamate in children with severe refractory epilepsy. Epilepsy Res 2001;47(1-2):1-7
   PubMedGoogle Scholar
• Hurst DL, Rolan TD. The use of felbamate to treat infantile spasms. J Child Neurol 1995;10(2):134-6
   PubMedGoogle Scholar
• Devinsky O, Kothari M, Rubin R, Felbamate for absence seizures [abstract]. Epilepsia 1992;33(Suppl 3):84
   PubMedGoogle Scholar
• Grosso S, Cordelli DM, Coppola G, Efficacy and safety of felbamate in children under 4 years of age: a retrospective chart review. Eur J Neurol 2008;15:940-6
   PubMed Web of Science ®Google Scholar
• Andrews CO, Fischer JH. Gabapentin: a new agent for the management of epilepsy. Ann Pharmacother 1994;28:1188-96
   PubMed Web of Science ®Google Scholar
• Wolf SM, Shinnar S, Kang H, Gabapentin toxicity in children manifesting as behavioral changes. Epilepsia 1995;36:1203-5
   PubMed Web of Science ®Google Scholar
• Trudeau V, Myers S, LaMoreaux L, Gabapentin in naıve childhood absence epilepsy: results from two double-blind, placebo-controlled, multicenter studies. J Child Neurol 1996;11:470-5
   PubMed Web of Science ®Google Scholar
• Appleton R, Fichtner K, LaMoreaux L, Gabapentin as add-on therapy in children with refractory partial seizures; a 12-week, multicentre, double-blind placebo-controlled study. Gabapentin Paediatric Study Group. Epilepsia 1999;40(8):1147-54
   PubMedGoogle Scholar
• Khurana DS, Riviello J, Helmers S, Efficacy of gabapentin therapy in children with refractory partial seizures. J Pediatr 1996;128(6):829-33
   PubMedGoogle Scholar
• Korn-Merker E, Borusiak P, Boenigk HE. Gabapentin in childhood epilepsy: a prospective evaluation of efficacy and safety. Epilepsy Res 2000;38:27-32
   PubMed Web of Science ®Google Scholar
• Glauser T, Ben-Menachem E, Bourgeois B, ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006;47:1094-120
   PubMed Web of Science ®Google Scholar
• Wheless JW, Clarke DF, Carpenter D. Treatment of pediatric epilepsy: expert opinion, 2005. J Child Neurol 2005;20:S1-56
   PubMedGoogle Scholar
• McDonald DG, Najam Y, Keegan MB, The use of lamotrigine, vigabatrin and gabapentin as add-on therapy in intractable epilepsy of childhood. Seizure 2005;14(2):112-16
   PubMedGoogle Scholar
• Barron TF, Hunt SL, Hoban TF, Price ML. Lamotrigine monotherapy in children. Pediatr Neurol 2000;23:160-3
   PubMed Web of Science ®Google Scholar
• Culy CR, Goa KL. Lamotriginre. A review of its use in childhood epilepsy. Pediatr Drugs 2000;2:299-330
   PubMedGoogle Scholar
• Guberman AH, Besag FMC, Brodie MJ, Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia 1999;40:985-91
   PubMed Web of Science ®Google Scholar
• Wong IC, Mawer GE, Sander JW. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother 1999;33(10):1037-42
   PubMedGoogle Scholar
• Motte J, Trevathan E, Arvidsson JF, Lamotrigine for generalized seizures associated with the Lennox–Gastaut syndrome. Lamictal Lennox–Gastaut Study Group. N Engl J Med 1997;337:1807-12
   PubMed Web of Science ®Google Scholar
• Buchanan N. The use of lamotrigine in juvenile myoclonic epilepsy. Seizure 1996;5:149-51
   PubMed Web of Science ®Google Scholar
• Veggiotti P, Cieuta C, Rex E, Dulac O. Lamotrigine in infantile spasms. Lancet 1994;344:1375-6
   PubMed Web of Science ®Google Scholar
• Ferrie CD, Robinson RO, Knott C, Panayiotopoulos CP. Lamotrigine as an add-on drug in typical absence seizures. Acta Neurol Scand 1995;91:200-2
   PubMed Web of Science ®Google Scholar
• Uldall P, Hansen FJ, Tonnby B. Lamotrigine in Rett syndrome. Neuropediatrics 1993;24:339-40
   PubMedGoogle Scholar
• Nieto-Barrera M, Brozmanova M, Capovilla G, ; Lamictal vs. Carbamazepine Study Group. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Res 2001;46(2):145-55
   PubMedGoogle Scholar
• Coppola G, Auriechio G, Federico R, Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an openlabel, randomized, parallel-group study. Epilepsia 2004;45(9):1049-53
   PubMedGoogle Scholar
• Frank LM, Enlow T, Holmes GL, Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia 1999;40:973-9
   PubMed Web of Science ®Google Scholar
• Biton V, Sackellares JC, Vuong A, Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology 2005;65(11):1737-43
   PubMedGoogle Scholar
• Duchowny M, Gilman J, Messenheimer J, ; LAMICTAL Pediatric Study Group. Long-term tolerability and efficacy of lamotrigine in pediatric patients with epilepsy. J Child Neurol 2002;17(4):278-85
   PubMedGoogle Scholar
• Welty TE, Gidal BE, Ficker DM, Privitera MD. LEV: a different approach to the pharmacotherapy of epilepsy. Ann Pharmacother 2002;36:296-304
   PubMed Web of Science ®Google Scholar
• Lynch BA, Lambeng N, Nocka F, The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug LEV. Proc Natl Acad Sci USA 2004;101:9861-6
   PubMed Web of Science ®Google Scholar
• Yang XF, Weisenfeld A, Rothman SM. Prolonged exposure to levetiracetam reveals a presynaptic effect on neurotransmission. Epilepsia 2007;48:1861-9
   PubMed Web of Science ®Google Scholar
• Carunchio I, Pieri M, Ciotti MT, Modulation of AMPA receptors in cultured cortical neurons induced by the antiepileptic drug LEV. Epilepsia 2007;48:654-62
   PubMedGoogle Scholar
• Rigo JM, Hans G, Nguyen L, The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA and glycine-gated currents. Br J Pharmacol 2002;136:659-72
   PubMed Web of Science ®Google Scholar
• Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002;43:9-18
   PubMed Web of Science ®Google Scholar
• French J. Use of levetiracetam in special populations. Epilepsia 2001;42(Suppl 4):40-3
   PubMedGoogle Scholar
• Glauser TA, Pellock JM, Bebin EM, Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia 2002;43:518-24
   PubMed Web of Science ®Google Scholar
• Vigevano F. Levetiracetam in pediatrics. J Child Neurol 2005;20:87-93
   PubMed Web of Science ®Google Scholar
• Chung AM, Eiland LS. Use of second-generation antiepileptic drugs in the pediatric population. Pediatr Drugs 2008;10(4):217-54
   PubMedGoogle Scholar
• Brodie MJ, Perucca E, Ryvlin P, Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007;68:402-8
   PubMed Web of Science ®Google Scholar
• Berkovic SF, Knowlton RC, Leroy RF, Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 2007;69:1751-60
   PubMed Web of Science ®Google Scholar
• Di Bonaventura C, Fattouch J, Mari F, Clinical experience with LEV in idiopathic generalized epilepsy according to different syndrome subtypes. Epileptic Disord 2005;7:231-5
   PubMedGoogle Scholar
• Andermann E, Andermann F, Meyvish P, Tonner F. Efficacy and tolerability LEV add-on therapy in patients with refractory idiopathic generalised epilepsy. Epilepsia 2006;47:187
   Google Scholar
• Glauser TA, Ayala R, Elterman RD, Double-blind placebocontrolled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology 2006;66:1654-60
   PubMed Web of Science ®Google Scholar
• Wheless JW, Ng YT. LEV in refractory pediatric epilepsy. J Child Neurol 2002;17:413-15
   PubMed Web of Science ®Google Scholar
• Lagae L, Buyes G, Ceulemans B. Clinical experience with LEV in childhood epilepsy: an add-on and monotherapy trial. Seizures 2005;14:66-71
   PubMed Web of Science ®Google Scholar
• Verrotti A, Coppola G, Manco R, LEV monotherapy for children and adolescentes with benign rolandic seizures. Seizure 2007;16:271-5
   PubMedGoogle Scholar
• Noachtar S, Andermann E, Meyvisch P, Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008;70:607-16
   PubMed Web of Science ®Google Scholar
• Bello-Espinosa LE, Roberts SL. Levetiracetam for benign epilepsy of childhood with centrotemporal spikes-three cases. Seizure 2003;12:157-9
   PubMedGoogle Scholar
• Garcia C, Rubio G. Efficacy and safety of levetiracetam in the treatment of Panayiotopoulos syndrome. Epilepsy Res 2009;85:318-20
   PubMedGoogle Scholar
• Verrotti A, Parisi P, Loiacono G, Levetiracetam monotherapy for childhood occipital epilepsy of gastaut. Acta Neurol Scand 2009;120:342-6
   PubMedGoogle Scholar
• Striano P, Coppola A, Pezzella M, An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology 2007;69:250-4
   PubMed Web of Science ®Google Scholar
• Papacostas S, Kkolou E, Papathanasiou E. Levetiracetam in three cases of progressive myoclonus epilepsy. Pharm World Sci 2007;29:164-6
   PubMedGoogle Scholar
• De Los Reyes EC, Sharp GB, Williams JP, Levetiracetam in the treatment of Lennox-Gastaut syndrome. Pediatr Neurol 2004;30:54-6
   PubMedGoogle Scholar
• Lawlor KM, Devlin AM. Levetiracetam in the treatment of infantile spasms. Eur J Paediatr Neurol 2005;9:19-22
   PubMed Web of Science ®Google Scholar
• Kumar SP, Smith PE. Levetiracetam as add-on therapy in generalised epilepsies. Seizure 2004;13:475-7
   PubMedGoogle Scholar
• Sharpe DV, Patel AD, Abou-Khalil B, Levetiracetam monotherapy in juvenile myoclonic epilepsy. Seizure 2008;17:64-8
   PubMed Web of Science ®Google Scholar
• Wheless JW. Levetiracetam in the treatment of childhood epilepsy. Neuropsychiatr Dis Treat 2007;3(4):409-21
   PubMedGoogle Scholar
• Lee YJ, Kang HC, Kim HD, Lee JS. Efficacy and safety of adjunctive levetiracetam therapy in pediatric intractable epilepsy. Pediatr Neurol 2010;42(2):86-92
   PubMedGoogle Scholar
• Li S, Cao J, Xiao N, Cai F. Efficacy and safety of levetiracetam as an add-on therapy in children aged less than 4 years with refractory epilepsy. J Child Neurol 2010;25(5):609-13
   PubMedGoogle Scholar
• Bialer M, Johannessen SI, Kupferberg HJ, Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res 1999;34:1-4
   PubMed Web of Science ®Google Scholar
• Phelps SJ, Wheless JW. Oxcarbazepine: a brief review. J Pediatr Pharmacol Ther 2005;10:248-53
   PubMedGoogle Scholar
• Tecoma ES. Oxcarbazepine. Epilepsia 1999;40(Suppl 5):S37-46
   PubMedGoogle Scholar
• French JA, Kanner AM, Bautista J, Efficacy and tolerability of the new antiepileptic drugs, II: treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2004;45:410-23
   PubMedGoogle Scholar
• Field MJ, Oles RJ, Singh L. Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity. Br J Pharmacol 2001;132:1-4
   PubMed Web of Science ®Google Scholar
• Dooley DJ, Donovan CM, Pugsley TA. Stimulus-dependent modulation of [(3)H] norepinephrine release from rat neocortical slices by gabapentin and pregabalin. J Pharmacol Exp Ther 2000;295:1086-93
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Wilson EA, Wesche DL, Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia 2005;46:1407-13
   PubMed Web of Science ®Google Scholar
• Lyrica. Summary of product characteristics. Pfizer Ltd; 2004
   Google Scholar
• Arroyo S, Anhut H, Kugler AR, Pregabalin add-on treatment: a randomized, doubleblind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 2004;45(1):20-7
   PubMedGoogle Scholar
• Beydoun A, Uthman BM, Kugler AR, ; Pregabalin 1008-009 Study Group. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 2005;64(3):475-80
   PubMedGoogle Scholar
• Elger CE, Brodie MJ, Anhut H, Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia 2005;46(12):1926-36
   PubMedGoogle Scholar
• French JA, Kugler AR, Robbins JL, Doseresponse trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003;60(10):1631-7
   PubMedGoogle Scholar
• Jan MMS, Zuberi SA, Alsaihati BA. Pregabalin: preliminary experience in intractable childhood epilepsy. Pediatr Neurol 2009;40:347-50
   PubMed Web of Science ®Google Scholar
• Brunner LA, Harrigan EP, John VA, Powell ML. Pharmacokinetics of a new anticonvulsant (CGP 33101) in epileptic male patients and healthy male subjects after single ascending oral doses of 400–1200 mg. Am J Ther 1994;1:215-20
   PubMedGoogle Scholar
• Arroyo S. Rufinamide. Neurotherapeutics 2007;4(1):155-62
   PubMed Web of Science ®Google Scholar
• Arroyo S, Sachdeo R, Rosenfeld W, Pharmacokinetics and safety of ascending doses of adjunctive rufinamide in pediatric patients with inadequately controlled seizures [abstract]. Epilepsia 2005;46(Suppl 8):193
   PubMedGoogle Scholar
• Wheless JW, Vazquez B. Rufinamide: a novel broad-spectrum antiepileptic drug. Epilepsy Curr 2010;10:1-6
   PubMed Web of Science ®Google Scholar
• Wheless J, Conry J, Krauss G, Safety and tolerability of rufinamide in children with epilepsy: a pooled analysis of seven clinical trials. J Child Neurol 2009;50:1158-66
   Google Scholar
• Brodie MJ, Rosenfeld W, Vazquez B, Efficacy and safety of rufinamide as adjunctive therapy in adult patients with inadequately controlled partial seizures [abstract]. Neurology 2006;66(Suppl 2):A35-6
   PubMedGoogle Scholar
• Elger C, Stefan H, Perdomo C, Arroyo S. Dose-response relationships of rufinamide in patients with inadequately controlled partial seizures [abstract]. Neurology 2006;66(Suppl 2):A37-8
   Google Scholar
• Brodie MJ, Rosenfeld WE, Vazquez B, Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia 2009;50(8):1899-909
   PubMed Web of Science ®Google Scholar
• Todorov A, Biton V, Krauss GL, Efficacy and safety of high- versus low-dose rufinamide monotherapy in patients with inadequately controlled partial seizures. Epilepsia 2005;46(Suppl 8):218-19
   Google Scholar
• Elger CE, Stefan H, Mann A, A 24-week multicenter, randomized, double-blind, parallel-group, dose-ranging study of rufinamide in adults and adolescents with inadequately controlled partial seizures. Epilepsy Res 2010;88:255-63
   PubMed Web of Science ®Google Scholar
• Glauser T, Kluger G, Sachdeo R, Efficacy and safety of rufinamide adjunctive therapy in patients with Lennox–Gastaut Syndrome (LGS): a multicenter, randomized, double-blind, placebo-controlled, parallel trial. Neurology 2005;64(Suppl 1):1826
   Google Scholar
• Glauser T, Kluger G, Sachdeo R, Open-label extension study of the efficacy and safety of rufinamide adjunctive therapy in patients with Lennox–Gastaut syndrome. Epilepsia 2005;46(Suppl 6):408
   Google Scholar
• Kluger G, Kurlemann G, Haberlandt E, Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience. Epilepsy Behav 2009;14:491-5
   PubMed Web of Science ®Google Scholar
• Perucca E. The clinical pharmacokinetics of the new antiepileptic drugs. Epilepsia 1999;40(Suppl 9):S7-13
   PubMedGoogle Scholar
• Ettinger AB, Bernal OG, Andriola MR, Two cases of nonconvulsive status epilepticus in association with TGB therapy. Epilepsia 1999;40:1159-62
   PubMed Web of Science ®Google Scholar
• Pereira J, Marson AG, Hutton JL. TGB add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2002;(3):CD001908
   PubMedGoogle Scholar
• Uldall P, Bulteau C, Pederson A, TGB adjunctive therapy in children with refractory epilepsy: a single-blind dose escalating study. Epilepsy Res 2000;42:159-68
   PubMed Web of Science ®Google Scholar
• Koepp MJ, Edwards M, Collins J, Status epilepticus and TGB therapy revisited. Epilpesia 2005;46:1625-32
   PubMedGoogle Scholar
• Ben-Menachem E. International experience with TGB add-on therapy. Epilepsia 1995;36:S14-21
   PubMedGoogle Scholar
• Boellner SW, McCarty J, Mercante D, Pilot study of TGB in children with partial seizures [abstract]. Epilepsia 1996;37:S92- 41
   Google Scholar
• Boellner SW, Deaton R, Sommerville KW. Long-term treatment of partial seizures with TGB in ehildren [abstact]. Epilepsia 1997;38:S208
   PubMedGoogle Scholar
• Al-jayyousi M, Helmers SL. TGB in the treatment of infantile spasms [abstract]. Epilepsia 1998;39:166
   Google Scholar
• Levisohn PM. Safety and tolerability of topiramate in children. J Child Neurol 2000;15:S22-6
   PubMedGoogle Scholar
• Grosso S, Galimberti D, Fametani MA, Efficacy and safety of topiramate in infants according to epilepsy syndromes. Seizure 2005;14:183-9
   PubMedGoogle Scholar
• Glauser TA, Levisohn PM, Ritter F, Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Epilepsia 2000;41:S86-90-25
   PubMedGoogle Scholar
• Glauser TA, Clark PO, MeGee K. Long-term response to topiramate in patients with West syndrome. Epilepsia 2000;41:S91-4
   PubMed Web of Science ®Google Scholar
• Philippi H, Boor R, Reitter B. Topiramate and metabolic acidosis in infants and toddlers. Epilepsia 2002;43:744-77
   PubMed Web of Science ®Google Scholar
• Arcas J, Ferrer T, Roche MC, Martinez A. Hypohidrosis related to the administration of topiramate to children. Epilepsia 2001;42(10):1363-5
   PubMedGoogle Scholar
• Biton V, Bourgeois BF. Topiramate in patients with juvenile myoclonic epilepsy. Arch Neurol 2005;62:1705-8
   PubMedGoogle Scholar
• Menachem EB, Sander JW, Stefan H, Topiramate monotherapy in the treatment of newly or recently diagnosed epilepsy. Clin Ther 2008;30(7):1180-95
   PubMedGoogle Scholar
• Marson AG. Topiramate add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev 2008;(3):CD001417
   PubMedGoogle Scholar
• Elterman RD, Glauser TA, Wyllie E, A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Neurology 1999;52:1338-44
   PubMed Web of Science ®Google Scholar
• Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs: a systematic review of their efficacy and tolerability. BMJ 1996;313(7066):1169-74
   PubMedGoogle Scholar
• Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997;314(7075):180-1
   PubMedGoogle Scholar
• Willmore LJ, Abelson MB, Menachem EB, Vigabatrin: 2008 Update. Epilepsia 2009;50(2):163-73
   PubMed Web of Science ®Google Scholar
• Kellermann K, Soditt V, Rambeck B, Fatal hepatotoxicity in a child treated with vigabatrin. Acta Neurol Scand 1996;93:380-1
   PubMedGoogle Scholar
• Uldall P, Alving J, Gram L, Hogenhaven H. Vigabatrin in childhood epilepsy: a 5-year follow-up study. Neuropediatrics 1995;26:253-6
   PubMedGoogle Scholar
• Chiron C, Dulac O, Beaumont D, Therapeutic trial of vigabatrin in refractory infantile spasms. J Child Neurol 1991;(Suppl 2):S52-9
   PubMedGoogle Scholar
• Elterman RD, Shields WD, Mansfield KA, Randomized trial of vigabatrin in patients with infantile spasms. Neurology 2001;57:1416-21
   PubMed Web of Science ®Google Scholar
• Lux AL, Edwards SW, Hancock E, The United Kingdom Infantile Spasms Study (UKISS) comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial. Lancet 2004;364:1773-8
   PubMed Web of Science ®Google Scholar
• Vigabatrin Paediatric Advisory Group. Guideline for prescribing vigabatrin in children has been revised. BMJ 2000;320:1404-5
   Google Scholar
• Riikonen R. Infantile spasms: therapy and outcome. J Child Neurol 2004;19:401-4
   PubMed Web of Science ®Google Scholar
• Gobbi G, Pini A, Bertani G, Prospective study of first-line vigabatrin monotherapy in childhood partial epilepsies. Epilepsy Res 1999;35:29-37
   PubMed Web of Science ®Google Scholar
• Ohtahara S. Zonisamide in the management of epilepsy—Japanese experience. Epilepsy Res 2006;68(Suppl 2):S25-33
   PubMedGoogle Scholar
• Brodie MJ, Duncan R, Vespignani H, Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 2005;46(1):31-41
   Google Scholar
• Frampton JE, Scott LJ. Zonisamide: a review of its use in the management of partial seizures in epilepsy. CNS Drugs 2005;19(4):347-67
   PubMedGoogle Scholar
• Low PA, James S, Peschel T, Zonisamide and associated oligohidrosis and hyperthermia. Epilepsy Res 2004;62:27-34
   PubMed Web of Science ®Google Scholar
• Kluger G, Zsoter A, Holthausen H. Long-term use of zonisamide in refractory childhood-onset epilepsy. Eur J Paediatr Neurol 2008;12(1):19-23
   PubMedGoogle Scholar
• Coppola G, Grosso S, Verrotti A, Zonisamide in children and young adults with refractory epilepsy: an open label, multicenter Italian study. Epilepsy Res 2009;83(2-3):112-16
   PubMedGoogle Scholar
• Kothare SV, Kaleyias J, Mostofi N, Efficacy and safety of zonisamide monotherapy in a cohort of children with epilepsy. Pediatr Neurol 2006;34(5):351-4
   PubMedGoogle Scholar
• Wilfong AA. Zonisamide monotherapy for epilepsy in children and young adults. Pediatr Neurol 2005;32(2):77-80
   PubMedGoogle Scholar
• Lotze TE, Wilfong AA. Zonisamide treatment for symptomatic infantile spasms. Neurology 2004;62(2):296-8
   PubMedGoogle Scholar
• Kothare SV, Valencia I, Khurana DS, Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. Epileptic Disord 2004;6(4):267-70
   PubMedGoogle Scholar
• Wilfong A, Schultz R. Zonisamide for absence seizures. Epilepsy Res 2005;64(1-2):31-4
   PubMedGoogle Scholar
• You SJ, Kang HC, Kim HD, Clinical efficacy of zonisamide in Lennox–Gastaut syndrome: Korean multicentric experience. Brain Dev 2008;30(4):287-90
   PubMed Web of Science ®Google Scholar
• Tan HJ, Martland TR, Appleton RE, Kneen R. Effectiveness and tolerability of zonisamide in children with epilepsy: a retrospective review. Seizure 2010;19(1):31-5
   Google Scholar